Iskender, D. Et Al. 2022. Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is associated with improved survival. European Review for Medical and Pharmacological Sciences , vol.26, no.3 , 957-965.

Iskender, D., Çakar, M., Dal, M., Baysal, N., Merdin, A., Bakirtas, M., ... Ulu, B.(2022). Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is associated with improved survival. European Review for Medical and Pharmacological Sciences , vol.26, no.3, 957-965.

Iskender, Dicle Et Al. "Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is associated with improved survival," European Review for Medical and Pharmacological Sciences , vol.26, no.3, 957-965, 2022

Iskender, Dicle Et Al. "Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is associated with improved survival." European Review for Medical and Pharmacological Sciences , vol.26, no.3, pp.957-965, 2022

Iskender, D. Et Al. (2022) . "Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is associated with improved survival." European Review for Medical and Pharmacological Sciences , vol.26, no.3, pp.957-965.

@article{article, author={Dicle Iskender Et Al. }, title={Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is associated with improved survival}, journal={European Review for Medical and Pharmacological Sciences}, year=2022, pages={957-965} }